Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2559 - Multicenter phase II study of biweekly XELIRI plus Bevacizumab as a second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study)


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer


Yoshiko Mori


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


Y. Mori1, N. Suzuki2, T. Nagasaka1, H. Tanioka3, Y. Iwamoto4, Y. Neki5, T. Yamatsuji6, M. Kobayashi7, M. Nakajima8, Y. Ojima9, S. Ikeda10, K. Kawamoto11, K. Shinozaki12, A. Tsuji13, T. Hinoi14, Y. Yamaguchi15, K. Yamashita3, M. Shimokawa16, M. Okajima9, S. Hazama8

Author affiliations

  • 1 Department Of Gastroenterological Surgery, Okayama University Hospital, 700-8558 - Okayama/JP
  • 2 2) department Of Digestive Surgery And Surgical Oncology, Yamaguchi University Graduate School of Medicine, 755-8505 - Ube/JP
  • 3 Department Of Medical Oncology, Okayama rosai Hospital, 702-8055 - Okayama/JP
  • 4 Department Of Medical Oncology, Hiroshima City Hospital, 730-0011 - Hiroshima/JP
  • 5 Department Of Medical Oncology, Kochi Health Sciences Center, 781-0111 - Kochi/JP
  • 6 Department Of General Surgery, Kawasaki Medical School,Kawasaki Hospital, 700-8505 - Okayama/JP
  • 7 Department Of Human Health And Medical Sciences, Kochi Medical School Hospital, 783-8505 - Nangoku/JP
  • 8 Department Of Digestive Surgery And Surgical Oncology, Yamaguchi University Graduate School of Medicine, 755-8505 - Ube/JP
  • 9 Department Of Surgery, Hiroshima City Hiroshima Citizens Hospital, 730-8518 - Hiroshima/JP
  • 10 Surgery, Hiroshima Prefectural Hospital, 734-0004 - Hiroshima/JP
  • 11 Department Of Surgery, Kurashiki Central Hospital, 710-8602 - Kurashiki/JP
  • 12 Department Of Medical Oncology, Hiroshima Prefectural Hospital, 734-0004 - Hiroshima/JP
  • 13 Department Of Clinical Oncology Faculty Of Medicine, Kagawa University, 761-0793 - Kita-gun/JP
  • 14 Department Of Surgery, Kure Medical Center and Chugoku Cancer Center, 737-0023 - Kure/JP
  • 15 Department Of Clinical Oncology, Kawasaki Medical School, 701-0192 - Kurashiki/JP
  • 16 Clinical Research Institute, National Kyushu Cancer Center, 811-1395 - Fukuoka/JP


Abstract 2559


Triweekly capecitabine plus irinotecan (XELIRI) is not completely regarded as a valid substitute for fluorouracil, leucovorin, and irinotecan (FOLFIRI) in metastatic colorectal cancer (mCRC) because of the potential for greater toxicity. Therefore, we conducted a phase II study to assess the efficacy and safety of biweekly XELIRI plus bevacizumab (BV) as second-line chemotherapy for mCRC. High dose BV (10 mg/kg) combined biweekly XELIRI as second-line chemotherapy was one of the first trial in the world.


Patients with mCRC who had received prior chemotherapy including oxaliplatin based regimen were eligible for this study. Protocol treatment administrated capecitabine 1,000 mg/m2 twice daily from the evening of day 1 to the morning of day 8, intravenous irinotecan 150mg/m2 on day 1, and BV 10 mg/kg on day 1 every 2 weeks. The primary endpoint of this study were progression-free survival (PFS) and safety. The secondary endpoint were overall survival (OS), time to treatment failure (TTF), response rate (RR) and disease control rate (DCR).


Between January 2013 and July 2015, 51 patients were enrolled in this study. The patients’ characteristics were as follows: median age, 66 years (range 41–82); male/female, 29/22; The median PFS was 5.7 months (95% confidence interval, 4.2–7.2 months). The median OS was 13.4 months (95%CI, 11.4–16.7 months). The median TTF was 5.2 months (95%CI, 3.9–7.2 months). The response rate was 14%, and the disease control rate was 78%. Grade 3 or higher adverse events were mainly febrile neutropenia in two patients and hypertension in 14 patients (28.6%). One patient had grade 4 intestinal pneumonia but improved by intensive treatment. There were no other severe adverse events or treatment-related deaths.


In mCRC patients, biweekly XELIRI + BV 10 mg/kg is effective and feasible as second-line chemotherapy. Biweekly XELIRI + BV is considered a useful substitute for FOLFIRI + BV in mCRC, and further study of this combination therapy is warranted.

Clinical trial identification

Legal entity responsible for the study

Japan Southwest Oncology Group


Japan Southwest Oncology Group


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.